About this trial
The aim of the current study is to assess the efficacy of TMS in the treatment of Complex Regional Pain Syndrome (CRPS). It is hypothesized that participants who receive TMS (Group 1) relative to sham treatment (Group 2) once daily for two days will demonstrate a greater improvement in CRPS-related pain and other associated symptomology (i.e., cognitive, emotional and physical) compared to baseline. Participants will be followed until they reach their baseline for two consecutive weeks to assess safety and duration of symptom alleviation.
Eligibility criteria
Qualifiers
Age 18-70
Diagnosis of CRPS (complex regional pain syndrome) for at least 3 months
Average pain level reported on Numerical Rating Scale meets entry criteria
Ability to perform the experimental task and procedures.
Disqualifiers
MRI contraindication (metal implants or devices, claustrophobia)
TMS Contraindication (eg metal implant or devices near the site of stimulation)
History of epilepsy
History of a psychological or psychiatric disorder that would interfere with study procedures, at the discretion of the researcher.
Trial design
Treatments tested in this trial
- Transcranial Magnetic Stimulation (TMS)
Treatment groups
Sponsors and collaborators
Stanford University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
Redlich Pain Endowment
Collaborator
Rocky Mountain Foundation
Collaborator
The Feldman Family Foundation Pain Research Fund
Collaborator